NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Motilal Oswal Q3FY26 Operating PAT up 16% YoY to ₹611 Cr; Declares ₹6 Dividend
Motilal Oswal Financial Services reported its highest-ever quarterly operating PAT of ₹611 crore for Q3FY26, marking a 16% YoY growth. The Asset and Private Wealth Management segments were major drivers, contributing approximately 50% of the group's operating profit. Total Assets Under Advice (AUA) crossed the ₹7 lakh crore milestone, while the Treasury book grew to ₹9,562 crore with an 18.5% XIRR since inception. The company also declared an interim dividend of ₹6 per share, maintaining its consistent shareholder payout policy.
முக்கிய அம்சங்கள்
Operating PAT grew 16% YoY to ₹611 Cr; Asset Management PAT surged 65% YoY to ₹227 Cr.Total Assets Under Advice (AUA) crossed ₹7 lakh Cr; Mutual Fund AUM grew 40% YoY.Treasury book reached ₹9,562 Cr with a healthy 18.5% XIRR since inception.Net worth increased to ₹13,632 Cr, representing a 24% CAGR over the last decade.Declared an interim dividend of ₹6 per equity share for the financial year.
👀 கவனிக்க வேண்டியவை
The significant shift towards high-margin, fee-based recurring revenue (74% of total) improves earnings stability and justifies a positive outlook. Investors should note the strong 26% ROE and the company's proven ability to compound net worth without external capital raises.
Motilal Oswal Financial Services (MOTILALOFS) reported a consolidated net profit of ₹569.16 crore for Q3 FY26, showing steady performance compared to ₹560.05 crore in the previous year. The company's total revenue from operations grew by approximately 11.9% year-on-year to ₹2,011.13 crore. A key highlight for shareholders is the declaration of an interim dividend of ₹6 per share (600% of face value). Additionally, the company successfully raised ₹300 crore through Non-Convertible Debentures (NCDs) during the quarter to bolster its capital position.
முக்கிய அம்சங்கள்
Declared an interim dividend of ₹6 per equity share of face value ₹1 each for FY 2025-26.Consolidated revenue from operations rose to ₹2,011.13 crore in Q3 FY26 from ₹1,797.36 crore in Q3 FY25.Consolidated Net Profit for the quarter stood at ₹569.16 crore with a basic EPS of ₹9.42.Raised ₹300 crore through Private Placement of Non-Convertible Debentures (NCDs) during the quarter.Nine-month (9M FY26) consolidated net profit reached ₹2,100.61 crore.
👀 கவனிக்க வேண்டியவை
Investors should view the ₹6 interim dividend and steady revenue growth as signs of strong operational health. The stock remains a solid play in the diversified financial services sector with consistent shareholder payouts.
BLAL Reports Nil Revenue and Net Loss of ₹46.04 Lakhs for Q3 FY26
BEML Land Assets Limited (BLAL) reported zero revenue from operations for the quarter ended December 31, 2025, reflecting its nature as a holding company for non-core assets. The company posted a net loss of ₹46.04 lakhs for the quarter, compared to a loss of ₹44.03 lakhs in the corresponding quarter of the previous year. For the nine-month period ended December 2025, the net loss widened to ₹373.68 lakhs from ₹332.88 lakhs year-on-year. Additionally, the company noted a regulatory non-compliance regarding the insufficient number of independent directors on its board.
முக்கிய அம்சங்கள்
Revenue from operations and total income remained at zero for the quarter ended December 31, 2025.Net loss for Q3 FY26 stood at ₹46.04 lakhs versus a loss of ₹44.03 lakhs in Q3 FY25.Total expenses for the nine-month period increased to ₹373.68 lakhs from ₹332.88 lakhs in the previous year.Negative reserves widened to ₹4,426.97 lakhs as of December 31, 2025, compared to ₹4,011.43 lakhs a year ago.The company is currently non-compliant with SEBI Listing Regulations regarding the required number of Independent Directors.
👀 கவனிக்க வேண்டியவை
As BLAL is a demerged entity holding surplus land assets, investors should focus on land monetization progress rather than quarterly earnings. The current lack of revenue and widening losses make the stock a speculative play on asset valuation.
Dr. Lal PathLabs Launches SOVAAKA Wellness Centre to Expand into Premium Preventive Care
Dr. Lal PathLabs has launched SOVAAKA, a premium wellness center in Gurugram, marking its entry into the high-growth preventive healthcare segment. The facility integrates advanced diagnostics like 1.5T MRI and genetic testing with AI-driven insights to offer personalized health programs. This strategic move aims to transition the company from disease detection to predictive wellness, targeting higher-margin lifestyle disease management. As of March 2025, the company operates 298 labs and over 6,607 service centers, providing a strong foundation for scaling such premium initiatives.
முக்கிய அம்சங்கள்
Launched SOVAAKA in Gurugram, a next-generation wellness center blending science and AI technology.Equipped with high-end diagnostic tools including 1.5T MRI, low-dose CT, and DEXA scanning.Offers specialized, doctor-designed programs like Eterna for women and Vita for men.Strategic focus on the growing preventive health market to address rising Non-Communicable Diseases.Company network includes 298 clinical labs and 12,365 pick-up points as of March 31, 2025.
👀 கவனிக்க வேண்டியவை
This expansion into premium wellness is a positive move to increase average revenue per patient; investors should watch for further rollouts of this format in other metros.
Motilal Oswal Shareholders Approve New Director Appointments with Over 99% Majority
Motilal Oswal Financial Services Limited (MOTILALOFS) has announced the successful passage of six key resolutions via postal ballot as of December 30, 2025. Shareholders approved the appointment and remuneration of Mr. Pratik Oswal and Mr. Vaibhav Agrawal as Non-Executive Directors. Additionally, two new Independent Directors, Mr. Joseph Conrad Agnelo D’Souza and Mr. Ashok Kumar Parasmal Kothari, were appointed to the board. All resolutions received overwhelming support, with most passing with over 99% of the votes in favor.
முக்கிய அம்சங்கள்
Appointment of Mr. Pratik Oswal as Non-Executive Director approved with 99.54% votes in favor.Appointment of Mr. Vaibhav Agrawal as Non-Executive Director approved with 99.33% votes in favor.Remuneration approvals for both Pratik Oswal and Vaibhav Agrawal received over 99.8% support from voting shareholders.Two new Independent Directors were appointed via special resolutions to strengthen board governance.A total of 2,41,544 shareholders were eligible for voting as of the November 21, 2025 cut-off date.
👀 கவனிக்க வேண்டியவை
These appointments represent a planned evolution of the company's leadership and governance; investors should view this as a routine strengthening of the board and no immediate action is required.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SCILAL Extends Capt. B. K. Tyagi's Additional Charge as CMD for 6 Months
The Ministry of Ports, Shipping and Waterways has approved the extension of Capt. B. K. Tyagi's additional charge as Chairman and Managing Director (CMD) of SCILAL. The extension is effective for a six-month period from January 1, 2026, to June 30, 2026, or until further orders. Capt. Tyagi, who is also the CMD of Shipping Corporation of India (SCI), brings over 35 years of industry experience to the role. This move ensures leadership continuity for the company, which manages the non-core land and assets demerged from SCI.
முக்கிய அம்சங்கள்
Extension of Capt. B. K. Tyagi's additional charge as CMD for a 6-month period.New term effective from January 1, 2026, through June 30, 2026.Capt. Tyagi concurrently serves as CMD of Shipping Corporation of India (SCI).Appointment is subject to final approval from the Appointments Committee of the Cabinet (ACC).Capt. Tyagi has over 35 years of experience in shipping, navigation, and general management.
👀 கவனிக்க வேண்டியவை
This is a routine administrative extension ensuring leadership stability. Investors should monitor for any future announcements regarding a permanent CMD appointment for the demerged entity.
Dr. Lal Path Labs Allots 8.37 Crore Bonus Shares in 1:1 Ratio
Dr. Lal Path Labs has completed the allotment of 8,37,75,510 bonus equity shares to eligible shareholders following its 1:1 bonus issue. The allotment was approved via a circular resolution on December 22, 2025, for shareholders on record as of December 19, 2025. This move doubles the company's total number of outstanding shares to 16,75,51,020. The paid-up equity share capital now stands increased at INR 167.55 crore, with the new shares ranking pari-passu with existing ones.
முக்கிய அம்சங்கள்
Allotment of 8,37,75,510 fully paid-up bonus equity shares of face value INR 10 each.Bonus issue executed in a 1:1 ratio for shareholders as of the December 19, 2025 record date.Total paid-up equity capital increased from INR 83.77 crore to INR 167.55 crore.Total number of equity shares outstanding increased to 16,75,51,020 shares.New bonus shares rank pari-passu in all respects with existing equity shares.
👀 கவனிக்க வேண்டியவை
Investors should note that while the number of shares in their portfolio has doubled, the stock price has been adjusted proportionally. No further action is required as the allotment is automatic for eligible shareholders.
Dr. Lal Path Labs Sets Dec 19 as Record Date for 1:1 Bonus Issue
Dr. Lal Path Labs Ltd. has officially fixed Friday, December 19, 2025, as the record date for its 1:1 bonus share issue. Eligible shareholders will receive one new fully paid-up equity share of INR 10 for every one existing share held. The deemed date for the allotment of these bonus shares is scheduled for December 22, 2025. This corporate action follows the approval previously granted by the company's members on December 08, 2025.
முக்கிய அம்சங்கள்
Bonus issue ratio confirmed at 1:1 (one new share for every one existing share).Record date for determining shareholder eligibility is December 19, 2025.Deemed date of allotment for the bonus equity shares is December 22, 2025.The face value of the equity shares remains unchanged at INR 10 per share.
👀 கவனிக்க வேண்டியவை
Investors should note that the stock price will adjust downward on the ex-bonus date to reflect the 1:1 ratio, while their total shareholding will double. To be eligible for the bonus, shares must be purchased before the ex-date.
MOTILALOFS Allots 30,000 NCDs aggregating to ₹300 Crore
Motilal Oswal Financial Services Limited has announced the allotment of 30,000 fully paid, secured, rated, redeemable, listed, senior Non-Convertible Debentures (NCDs). The face value of each NCD is ₹1,00,000, aggregating to a total issue size of ₹300 Crore. These NCDs are proposed to be listed on the National Stock Exchange of India Limited (NSE). The tenure of the instrument is 3 years, maturing on December 12, 2028, with coupon payments annually.
முக்கிய அம்சங்கள்
Allotted 30,000 Secured NCDsEach NCD has a face value of ₹1,00,000Total issue size aggregates to ₹300 CroreNCDs mature on December 12, 2028Coupon payments are scheduled annually
👀 கவனிக்க வேண்டியவை
Investors should review the terms of the NCDs, including the coupon rate and security details, as outlined in the General Information Document (GID) and Key Information Document (KID). Monitor the company's ability to maintain a minimum security cover of 1.00 times the outstanding principal amounts of the NCDs.
Dr. Lal PathLabs Q2 FY26 Net Profit Rises 16.4% YoY to ₹152 Cr; 1:1 Bonus Issue Approved
Dr. Lal PathLabs reported a steady performance for Q2 FY26, with revenue from operations growing 10.7% YoY to ₹730.6 crore. Net profit for the quarter increased by 16.4% YoY to ₹152.2 crore, supported by a 10.8% growth in H1 revenue reaching ₹1,400.4 crore. The company's board has approved a 1:1 bonus issue and a second interim dividend of ₹7 per share, reflecting strong cash flows and management confidence. Operational highlights include the successful integration of Suburban Diagnostics' business into the parent entity following its voluntary liquidation.
முக்கிய அம்சங்கள்
Revenue from operations increased 10.7% YoY to ₹7,306 million in Q2 FY26.Consolidated Net Profit rose 16.4% YoY to ₹1,522 million compared to ₹1,308 million in the previous year.Board approved a 1:1 bonus issue (one bonus share for every one share held) subject to shareholder approval.Declared a second interim dividend of ₹7 per equity share for FY26.Basic Earnings Per Share (EPS) improved to ₹18.05 from ₹15.52 in the same quarter last year.
👀 கவனிக்க வேண்டியவை
The consistent double-digit growth in profit and the announcement of a 1:1 bonus issue are strong positive signals for long-term investors. Maintain a positive outlook on the stock while monitoring the integration benefits of the Suburban Diagnostics business.
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore
Dr. Lal PathLabs has received shareholder approval via postal ballot to significantly increase its authorized share capital. The limit has been raised from INR 107.96 crore to INR 200 crore, effectively doubling the company's capacity to issue new equity. This change involves a formal amendment to Clause V of the Memorandum of Association. While this is a regulatory enabling provision, it often serves as a precursor to future corporate actions such as bonus issues, rights issues, or equity-based fundraising.
முக்கிய அம்சங்கள்
Authorized share capital increased from INR 107.96 crore to INR 200 crore.Shareholder approval was obtained through a postal ballot concluded on December 07, 2025.The new capital structure consists of 20,00,00,000 equity shares with a face value of INR 10 each.Amendment to Clause V of the Memorandum of Association (MOA) has been officially implemented.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company for upcoming announcements regarding bonus issues or capital raises, as this move creates the necessary legal headroom for such actions.
Dr. Lal PathLabs Shareholders Approve Bonus Issue and New 2025 Employee Stock Unit Plan
Dr. Lal PathLabs has announced the successful passage of seven resolutions via postal ballot, most notably the issuance of bonus equity shares and an increase in authorized share capital. The 'Employee Restricted Stock Unit Plan 2025' was approved with 79.81% favor, although it faced significant institutional dissent with 51.5% of institutional votes cast against it. Additionally, shareholders cleared the path for secondary share acquisitions through a trust and a reduction in the 2022 options reserve. These approvals facilitate the company's capital restructuring and long-term incentive programs.
முக்கிய அம்சங்கள்
Bonus Equity Shares issuance approved with 98.04% of total votes in favor.Increase in Authorized Share Capital passed with a near-unanimous 99.84% majority.New 'Employee Restricted Stock Unit Plan 2025' secured 79.81% support despite 51.5% institutional pushback.Secondary acquisition of shares through a Trust route for ESOP implementation approved by 83.76% of voters.Reduction of Options Reserve under the 2022 ESOP plan approved with 86.80% majority.
👀 கவனிக்க வேண்டியவை
Investors should view the bonus issue as a positive move for share liquidity, though the high institutional dissent on the new ESOP plan suggests a need to monitor future management compensation and dilution.
Motilal Oswal to Raise Rs 300 Crore via Private Placement of NCDs
Motilal Oswal Financial Services' Finance Committee has approved the issuance of up to 30,000 Non-Convertible Debentures (NCDs) to raise Rs 300 crore. These NCDs are secured, rated, and will be issued on a private placement basis with a face value of Rs 1,00,000 each. The tenure for these senior bonds is set at 3 years, and they will be listed on the National Stock Exchange. This move is aimed at strengthening the company's capital position for its ongoing business operations.
முக்கிய அம்சங்கள்
Issuance of up to 30,000 secured NCDs with a face value of Rs 1,00,000 each.Total fundraise amount aggregates up to Rs 300 crore via private placement.The NCDs have a fixed tenure of 3 years and will be listed on the NSE.Security cover of 1.00x maintained through hypothecation of company receivables.
👀 கவனிக்க வேண்டியவை
This is a routine capital-raising activity for a financial services firm; investors should track the cost of debt and its impact on overall margins.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
